Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Multiple Myeloma 45Recurrence 14Lymphoma 6Neoplasms 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 4Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Glioblastoma 2Amyloidosis 2Wilms Tumor 1Vomiting 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ototoxicity 1Osteosarcoma 1Obesity 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Radiotherapy 5Gemcitabine 4Cyclophosphamide 4pazopanib 3Docetaxel 3Biopsy 3pembrolizumab 2olaparib 2liposomal doxorubicin 2Vincristine 2Trastuzumab 2Trabectedin 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Proton Therapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Filgrastim 2Etoposide 2Drug Therapy 2Doxorubicin 2Celecoxib 2Carboplatin 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trastuzumab biosimilar HLX02 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma × Dexamethasone × Clear all
NCT01236586 2017-07-02

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinaryLymphoidSarcoma

Brain Neoplasms, Lymphoma, Neoplasms, Wilms Tumor, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡